Zolbetuximab Plus Chemotherapy as First-Line Treatment in Patients with Claudin 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: Korean Population Subgroup—Combined Efficac
Zolbetuximab plus chemotherapy demonstrated favorable PFS and OS versus placebo plus chemotherapy in the Korean subgroup, with numerically greater efficacy compared with the overall pooled population. This may be potentially attributable to low rates of zolbetuximab discontinuation and toxicity management.
Authors
- Jeonghee Lee (ORCID: https://orcid.org/0000-0001-9072-6507)
- Young Iee Park
- Byoung Yong Shim (ORCID: https://orcid.org/0000-0001-6473-786X)
- Sun Jin Sym (ORCID: https://orcid.org/0000-0002-1340-6291)
- Jwa Hoon Kim (ORCID: https://orcid.org/0000-0002-0838-0111)
- Min Yi (ORCID: https://orcid.org/0000-0001-8662-6546)
- Eun‐Kee Song (ORCID: https://orcid.org/0000-0001-8836-0294)
- Seok Yun Kang (ORCID: https://orcid.org/0000-0002-4995-9912)
- Do‐Youn Oh (ORCID: https://orcid.org/0000-0003-1663-9901)
- Jong Gwang Kim (ORCID: https://orcid.org/0000-0002-7615-5864)
- Hong Jae Chon (ORCID: https://orcid.org/0000-0002-6979-5812)
- Keun‐Wook Lee (ORCID: https://orcid.org/0000-0002-8491-703X)
- Min‐Hee Ryu (ORCID: https://orcid.org/0000-0002-1033-1263)
- Jin‐Soo Kim (ORCID: https://orcid.org/0000-0002-6038-6182)
- In-Ho Kim (ORCID: https://orcid.org/0000-0003-1339-3459)
- Sanghee Cho (ORCID: https://orcid.org/0000-0001-6715-9348)
- Won Ki Kang
- Hyung-Don Kim
- Sang Cheul Oh
Institutions
- Ulsan College (KR)
- Seoul National University (KR)
- Korea University Medical Center (KR)
- Kyungpook National University Hospital (KR)
- Asan Medical Center (KR)
- Samsung Medical Center (KR)
- Seoul National University Hospital (KR)
- Seoul National University Bundang Hospital (KR)
- University of Ulsan (KR)
- Gachon University Gil Medical Center (KR)
- The Catholic University of Korea St. Vincent's Hospital (KR)
- SNUH SMG-SNU Boramae Medical Center (KR)
- National Cancer Center (KR)
- Jeonbuk National University Hospital (KR)
- CHA University Bundang Medical Center (KR)
- Astellas Pharma (South Korea) (KR)
- Chonnam National University Hwasun Hospital (KR)
- CHA University (KR)
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Ajou University (KR)
- Jeonbuk National University (KR)
- Sungkyunkwan University (KR)
- Catholic University of Korea (KR)
Publication Details
- Journal
- Cancer Research and Treatment
- Published
- 2025-12-05
- DOI
- https://doi.org/10.4143/crt.2025.935
- Primary Topic
- Barrier Structure and Function Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Handok
- BeiGene
- Yuhan
- Astellas Pharma
- Servier
- Daiichi Sankyo Europe